SER 262

Drug Profile

SER 262

Alternative Names: SER-262; SER-262 - Designed Ecobiotic®

Latest Information Update: 11 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Seres Therapeutics
  • Class Antibacterials; Bacteria
  • Mechanism of Action Bacteria replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Clostridium infections

Most Recent Events

  • 07 Jul 2016 Phase-I clinical trials in Clostridium infections (Prevention) in USA (PO) (NCT02830542)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top